Bachem Holding AGBCHMF 91 Return-on-Tangible-Equity is 14.40% as of Dec. 2025, which is 23% above its 10-year median of 11.72. GuruFocus rates BCHMF with a GF Score™ of 91/100 and a GF Value™ of $98.61 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,200 Biotechnology companies, Bachem Holding AG ranks better than 87.42% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bachem Holding AG's annualized net income for the quarter that ended in Dec. 2025 was $247.7 Mil. Bachem Holding AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $1,719.5 Mil. Therefore, Bachem Holding AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 14.40%.
The historical rank and industry rank for Bachem Holding AG's Return-on-Tangible-Equity or its related term are showing as below:
BCHMF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.9 Med: 11.72 Max: 17.41
Current: 10.79
During the past 13 years, Bachem Holding AG's highest Return-on-Tangible-Equity was 17.41%. The lowest was 8.90%. And the median was 11.72%.
BCHMF's Return-on-Tangible-Equity is ranked better than 87.42% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs BCHMF: 10.79
Bachem Holding AG (OTCPK:BCHMF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bachem Holding AG Return-on-Tangible-Equity Related Terms
Bachem Holding AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCHMF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Bachem Holding AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.40% mean?
Bachem Holding AG (BCHMF) has a Return-on-Tangible-Equity of 14.40% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bachem Holding AG and its competitors. This is 23% above median its historical median of 11.72. Over the past decade, Bachem Holding AG's Return-on-Tangible-Equity has ranged from 8.90 to 17.41. According to the industry distribution chart, Bachem Holding AG ranks #151 out of 1200 companies in the Biotechnology industry, placing it in the top 12.6%.
Is Bachem Holding AG's Return-on-Tangible-Equity too high?
Bachem Holding AG's current Return-on-Tangible-Equity of 14.40% is 23% above median its 10-year median of 11.72. Over the past 10 years, this metric has ranged from a low of 8.90 to a high of 17.41. Based on the distribution chart, Bachem Holding AG ranks #151 out of 1200 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bachem Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #151 out of 1200 companies for Return-on-Tangible-Equity. This places Bachem Holding AG in the top 13% of its industry — outperforming the majority of peers. Historically, Bachem Holding AG's own Return-on-Tangible-Equity has ranged from 8.90 to 17.41 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bachem Holding AG and its competitors. Bachem Holding AG's current Return-on-Tangible-Equity is 14.40%, which is 23% above median its own 10-year median of 11.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $98.61, compared to a current price of $87.34 — trading 11.4% below its estimated fair value. The current Return-on-Tangible-Equity is 14.40%, which is 23% above median its 10-year median of 11.72. Bachem Holding AG's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current Return-on-Tangible-Equity is 14.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $87.34 is trading 11.4% below its estimated GF Value™ of $98.61.
GuruFocus considers Bachem Holding AG to be Modestly Undervalued.
Key valuation signals for BCHMF:
Return-on-Tangible-Equity: 14.40% (23% above median its 10-year median of 11.72)
GF Value™: $98.61 vs. price of $87.34 (11.4% below fair value)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
91GF Score
Get the complete analysis for BCHMF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
